siRNA and antisense oligonucleotide drugs
中文As of 2026-11-01, Drugnews tracks 8 Asian programs in siRNA and antisense oligonucleotide drugs across China, Japan, Korea and Taiwan; the most advanced is NS-065/NCNP-01 from Nippon Shinyaku Co., Ltd. / National Center of Neurology and Psychiatry (Approved).
Assets (8)
| Company | Country | Asset | Mechanism / format | Highest stage | Indication | Partner |
|---|---|---|---|---|---|---|
| Nippon Shinyaku Co., Ltd. / National Center of Neurology and Psychiatry | Japan | NS-065/NCNP-01 viltolarsen | DMD exon 53 ASO | Approved | Duchenne muscular dystrophy amenable to exon 53 skipping | NS Pharma, Inc. (United States) |
| Japan | NS-089/NCNP-02 brogidirsen | DMD exon 44 ASO | Phase 2 | Duchenne muscular dystrophy amenable to exon 44 skipping | NS Pharma, Inc. (United States development subsidiary) | |
| Shanghai Argo Biopharmaceutical Co., Ltd. | China | BW-20829 (DII235) | LPA / lipoprotein(a) siRNA | Phase 2 | Elevated lipoprotein(a) and atherosclerotic cardiovascular disease | Novartis |
| China | BW-00163 (QCZ484) | AGT (angiotensinogen) siRNA | Phase 2 | Mild to moderate hypertension | Novartis | |
| Suzhou Ribo Life Science Co., Ltd. | China | RBD4059 vortosiran | FXI (coagulation factor XI) siRNA | Phase 2 | Chronic / stable coronary artery disease | — |
| China | RBD5044 | APOC3 siRNA | Phase 2 | Mixed dyslipidemia / hypertriglyceridemia | — | |
| SanegeneBio / Suzhou Sanegene Bio Inc. | China | SGB-9768 | C3 (complement component 3) siRNA | Phase 2 | Complement-mediated kidney diseases: IgAN, C3G and primary IC-MPGN | — |
| China | SGB-3908 (IBI3016) | AGT (angiotensinogen) siRNA | Phase 1 | Hypertension | — |
Asian outbound licensing (3)
| Date | Licensor | Country | Partner | Asset / portfolio | Territory | Upfront | Potential total |
|---|---|---|---|---|---|---|---|
| 2024-01-07 | Shanghai Argo Biopharmaceutical Co., Ltd. | China | Novartis Pharma AG | One Phase 1 cardiovascular program; one Phase 1/2a cardiovascular program; research collaboration and options covering up to two additional cardiovascular targets | Worldwide for one clinical program; ex-Greater China for the other; worldwide options for additional targets | USD 185.0m | USD 4165.0m |
| 2025-09-03 | Argo Biopharmaceutical Co., Ltd. | China | Novartis | Options for two discovery-stage next-generation molecules; right of first negotiation for BW-00112 (ANGPTL3); license for an additional IND-enabling hepatic siRNA candidate | Ex-China licenses/options with reciprocal United States and China profit-and-loss options | USD 160.0m | — |
| 2024-01-03 | Suzhou Ribo Life Science Co., Ltd. / Ribocure AB | China | Boehringer Ingelheim | Multi-target liver-directed siRNA collaboration using RIBO-GalSTAR | 查無 | — | — |
FAQ
How many Asian programs are tracked?
The 2026-11-01 table contains 8 programs in 4 originator groups.
Which program is the most advanced?
NS-065/NCNP-01 from Nippon Shinyaku Co., Ltd. / National Center of Neurology and Psychiatry is at Approved, the highest stage represented in this table.
Which companies and countries are represented?
Nippon Shinyaku Co., Ltd. / National Center of Neurology and Psychiatry; SanegeneBio / Suzhou Sanegene Bio Inc.; Shanghai Argo Biopharmaceutical Co., Ltd.; Suzhou Ribo Life Science Co., Ltd.. Companies in this table originate from China, Japan.
Which drug formats are included?
ASO, siRNA. Stages and indications are listed separately for each program.
How are licensing deal values reported?
The table lists 3 outbound licensing events. Upfront payments and potential total values are separate, original currencies are retained, undisclosed amounts remain blank, and portfolio amounts are not allocated to individual assets.